MEI Pharma To Consider Strategic Alternatives; Will Commence A Reduction-In-Force Beginning As Soon As Practicable And Continuing In Stages As The Co's Operational And Strategic Direction Evolves; Intends To Promptly Discontinue The Clinical...
MEI Pharma To Consider Strategic Alternatives; Will Commence A Reduction-In-Force Beginning As Soon As Practicable And Continuing In Stages As The Co's Operational And Strategic Direction Evolves; Intends To Promptly Discontinue The Clinical...
In order to best preserve the Company's existing cash, the Company will commence a reduction-in-force beginning as soon as practicable and continuing in stages as the Company's operational and strategic direction evolves. The Company intends to promptly discontinue the clinical development of voruciclib, while certain non-clinical activities related to MEI's drug candidate assets will continue to be conducted by the Company.MEI Pharma To Consider Strategic Alternatives; Will Commence A Reduction-In-Force Beginning As Soon As Practicable And Continuing In Stages As The Co's Operational And Strategic Direction Evolves; Intends To Promptly Discontinue The Clinical Development Of Voruciclib
MEI Pharma将考虑战略性选择；将尽快开始并分阶段进行裁员，以响应公司的运营和战略方向的变化；打算迅速终止Voruciclib的临床开发。
Company Commences a Cash Preservation Plan Including a Reduction in Force
公司启动现金储备计划，包括裁员
MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today announced that its Board of Directors has determined unanimously to begin evaluation of the Company's strategic alternatives, including potential transactions as well as an orderly wind down of the Company, if appropriate, in order to maximize the value of its assets for its stockholders. The Company intends to evaluate and engage a financial advisor to assist in this process.
MEI Pharma，Inc.（NASDAQ：MEIP）（以下简称“公司”）今天宣布，其董事会一致决定开始评估公司的战略选择，包括潜在交易以及有条不紊地关闭公司（如果适当的话），以最大化其资产对股东的价值。公司打算评估并聘请财务顾问以协助这一进程。
In order to best preserve the Company's existing cash, the Company will commence a reduction-in-force beginning as soon as practicable and continuing in stages as the Company's operational and strategic direction evolves. The Company intends to promptly discontinue the clinical development of voruciclib, while certain non-clinical activities related to MEI's drug candidate assets will continue to be conducted by the Company.
为了最好地保留公司现有的现金，公司将尽快开始减少人员，并随着公司的运营和战略方向的演变而分阶段进行。公司打算立即停止voruciclib的临床开发，而涉及MEI候选药物资产的某些非临床活动将继续由公司进行。